Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
48 hedge funds and large institutions have $14.8M invested in Sio Gene Therapies Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 8 closing their positions.
146% more call options, than puts
Call options by funds: $4.08M | Put options by funds: $1.66M
0% more funds holding
Funds holding: 48 → 48 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
32% less capital invested
Capital invested by funds: $21.8M → $14.8M (-$6.98M)
41% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$545K |
| 2 |
Renaissance Technologies
New York
|
+$235K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$207K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$152K |
| 5 |
EWM
Edge Wealth Management
New York
|
+$148K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.71M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.5M |
| 3 |
BlackRock
New York
|
-$1.45M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$262K |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$237K |
SIOX Hedge Fund Activity: Q4 2019 in Review
48 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q4 2019, worth a combined $14.8M — down 32% from $21.8M a quarter earlier.
Fund positioning in SIOX was balanced in Q4 2019: 8 funds opened new positions, 8 closed out, 10 added to existing stakes and 17 trimmed.
The largest buyer was Hudson Bay Capital Management, adding an estimated $545K. The largest seller was Citadel Advisors, cutting an estimated $2.71M.
- 48 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $14.8M of Sio Gene Therapies Inc. Common Stock stock for Q4 2019, down 32% quarter-over-quarter.
- 8 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q4 2019 and 8 closed out, a net change of 0 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q4 2019 was Hudson Bay Capital Management, an estimated $545K added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q4 2019 was Citadel Advisors, an estimated $2.71M sold.
Based on aggregated 13F filings for Q4 2019.